Delayed autoimmune haemolytic anaemia after artesunate therapy for severe malaria

Loading...
Thumbnail Image

Date

Journal Title

Journal ISSN

Volume Title

Publisher

BMJ Publishing Group

Abstract

We report the case of a 51-year-old man with severe malaria, who developed delayed autoimmune haemolytic anaemia following artesunate therapy. Delayed autoimmune haemolytic anaemia following artesunate therapy has been previously described. Its diagnosis can be challenging in the setting of possible dengue coinfection. Clinicians should be vigilant of this potential side effect of artesunate therapy, especially in patients who later develop signs and symptoms of haemolytic anaemia. © 2022 BMJ Publishing Group. All rights reserved.

Description

Keywords

Infectious diseases, Malignant and benign haematology, Anemia, hemolytic, autoimmune, Antimalarials, Artesunate, Humans, Malaria, Malaria, falciparum, Male, Middle aged, Adalimumab, Chloroquine, Haptoglobin, Hemoglobin, Immunoglobulin m, Lactate dehydrogenase, Antimalarial agent, Adult, Article, Autoimmune hemolytic anemia, Case report, Chill, Clinical article, Coombs test, Crohn disease, Delayed autoimmune hemolytic anemia, Disease severity, Erythrocyte transfusion, Fatigue, Fever, Follow up, Hemoglobin blood level, Human, Immunotherapy, Lactate dehydrogenase blood level, Malaise, Malaria falciparum, Pallor, Parasitemia, Plasmodium falciparum, Platelet count, Prophylaxis, Protein blood level, Reticulocyte count, Schistocyte, Smear, Sweating, Thrombocytopenia, Weakness

Citation

Endorsement

Review

Supplemented By

Referenced By